Patient and Physician Knowledge of Key Safety Messages

CompletedOBSERVATIONAL
Enrollment

2,227

Participants

Timeline

Start Date

September 15, 2014

Primary Completion Date

February 21, 2020

Study Completion Date

April 15, 2020

Conditions
Anticoagulation
Interventions
BEHAVIORAL

Rivaroxaban (Xarelto, BAY59-7939)

Survey to measure physician awareness and understanding of the key messages in the prescriber guide.

BEHAVIORAL

Rivaroxaban (Xarelto, BAY59-7939)

Survey to measure patient awareness and understanding of the key messages in the patient card.

Trial Locations (4)

Unknown

Multiple Locations

Multiple Locations

Multiple Locations

Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

collaborator

RTI Health Solutions

OTHER

lead

Bayer

INDUSTRY

NCT01907048 - Patient and Physician Knowledge of Key Safety Messages | Biotech Hunter | Biotech Hunter